VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Suppr

超能文献

作者信息

Cavalli F, Sonntag R W, Jungi F, Senn H J, Brunner K W

出版信息

Cancer Treat Rep. 1978 Mar;62(3):473-5.

PMID:348319

Abstract

摘要

相似文献

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Cancer Treat Rep. 1978 Mar;62(3):473-5.

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

Cancer Treat Rep. 1977 May-Jun;61(3):489-90.

[A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].

Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):931-7.

[Treatment of anaplastic carcinoma of the lung with VP 16-213].

Med Clin (Barc). 1982;79(7):322-4.

[A phase II study of oral VP-16 in primary lung cancer].

Gan To Kagaku Ryoho. 1985 Sep;12(9):1801-7.

[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].

Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21.

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

Cancer Treat Rep. 1979 Aug;63(8):1231-9.

Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.

Semin Oncol. 1985 Mar;12(1 Suppl 2):21-2.

[Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].

Nihon Gan Chiryo Gakkai Shi. 1986 Feb 20;21(1):12-8.

[Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma].

Nihon Gan Chiryo Gakkai Shi. 1986 Feb 20;21(1):108-11.

引用本文的文献

Chemotherapy advances in small-cell lung cancer.

J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S565-78. doi: 10.3978/j.issn.2072-1439.2013.07.43.

Inhibition of tumor angiogenesis by oral etoposide.

Exp Ther Med. 2010 Sep;1(5):739-746. doi: 10.3892/etm.2010.127. Epub 2010 Jul 21.

Pharmacokinetic optimisation of treatment with oral etoposide.

Clin Pharmacokinet. 2004;43(7):441-66. doi: 10.2165/00003088-200443070-00002.

Qual Life Res. 2002 May;11(3):235-48. doi: 10.1023/a:1015257121369.

Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.

Med Oncol. 2001;18(4):269-75. doi: 10.1385/MO:18:4:269.

Treatment and outcomes for elderly patients with small cell lung cancer.

Drugs Aging. 2000 Sep;17(3):229-47. doi: 10.2165/00002512-200017030-00006.

The role of oral etoposide in non-small cell lung cancer.

Drugs. 1999;58 Suppl 3:21-30. doi: 10.2165/00003495-199958003-00004.

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

Br J Cancer. 1998 Jun;77(11):1961-5. doi: 10.1038/bjc.1998.325.

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Br J Cancer. 1996 Sep;74(6):980-4. doi: 10.1038/bjc.1996.469.

Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer.

Jpn J Cancer Res. 1996 Aug;87(8):856-61. doi: 10.1111/j.1349-7006.1996.tb02111.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验